Ion channels present an important target class associated with a broad spectrum of diseases, opening the door to novel therapies for treating conditions that can be difficult to drug. However, while ion channel targets carry incredible potential, they can be challenging to work with, often demonstrate pharmacological promiscuity, and represent a significant early discovery investment. It is therefore crucial to manage risks to clinical success and patients carefully and proactively from the earliest drug discovery phases.
In this webinar, we will present an introduction to ion channels and how they can be leveraged in drug discovery, with examples around pain and neurology. Next, dive into screening cascade design and how to successfully execute high-throughput hit discovery on a scale of hundreds of thousands.
Finally, we will discuss risk mitigation through early selectivity screening, and how to effectively progress ion channel hits through hit-to-lead and lead optimization, before welcoming your questions and discussion points.
Register now to update and expand your knowledge on how to successfully conduct ion channel hit discovery, and how to select and optimize the most promising hits for continued preclinical development.
RegisterKey Learning Objectives
- Explore how ion channel targets can provide access to attractive yet challenging new therapies
- Understand how to manage risk and optimize investment when breaking new ground with ion channels
- Learn how to construct a successful high-throughput screening cascade for ion channel hit discovery using the Sophion Qube, and review case study data from the largest known ion channel electrophysiology screen
- Find out how to best leverage early selectivity screening to mitigate the risk of pharmacological promiscuity inherent to ion channels
